Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (241-250 of 338) with videos related to

Pageof 34
Sort By:
Journal of Neuro-Oncology|September 17, 2015
Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancerKyung Rae Cho, Min Ho Lee, Doo-Sik Kong, et al.
Journal for Immunotherapy of Cancer|May 18, 2019
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinomaSehhoon Park, Je-Gun Joung, Yang Won Min, et al.
Investigational New Drugs|April 10, 2017
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumorsSu Jin Lee, Seon Young Lee, Weon Sup Lee, et al.
Cancer Research and Treatment|August 4, 2011
Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancerSu Jin Lee, Silvia Park, Hee Kyung Ahn, et al.
British Journal of Cancer|January 31, 2018
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)Jong-Mu Sun, Ki Hyeong Lee, Bong-Seog Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2019
The First-week Proliferative Response of Peripheral Blood PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts the Response to Anti-PD-1 Therapy in Solid TumorsKyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint InhibitorYoujin Kim, Chu Hyun Kim, Ho Yun Lee, et al.
Molecular Cancer Research : MCR|June 17, 2010
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptorHae Hyun Jung, Yeon Hee Park, Hyun Jung Jun, et al.
Future Oncology (London, England)|February 9, 2019
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancerKen Kato, Manish A Shah, Peter Enzinger, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2014
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?Ji Yun Lee, Sung Hee Lim, Moonjin Kim, et al.
Pageof 34

Showing results (241-250 of 338) with videos related to

Sort By:
Pageof 34
Journal of Neuro-Oncology|September 17, 2015
Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancerKyung Rae Cho, Min Ho Lee, Doo-Sik Kong, et al.
Journal for Immunotherapy of Cancer|May 18, 2019
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinomaSehhoon Park, Je-Gun Joung, Yang Won Min, et al.
Investigational New Drugs|April 10, 2017
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumorsSu Jin Lee, Seon Young Lee, Weon Sup Lee, et al.
Cancer Research and Treatment|August 4, 2011
Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancerSu Jin Lee, Silvia Park, Hee Kyung Ahn, et al.
British Journal of Cancer|January 31, 2018
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)Jong-Mu Sun, Ki Hyeong Lee, Bong-Seog Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2019
The First-week Proliferative Response of Peripheral Blood PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts the Response to Anti-PD-1 Therapy in Solid TumorsKyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint InhibitorYoujin Kim, Chu Hyun Kim, Ho Yun Lee, et al.
Molecular Cancer Research : MCR|June 17, 2010
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptorHae Hyun Jung, Yeon Hee Park, Hyun Jung Jun, et al.
Future Oncology (London, England)|February 9, 2019
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancerKen Kato, Manish A Shah, Peter Enzinger, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2014
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?Ji Yun Lee, Sung Hee Lim, Moonjin Kim, et al.
Pageof 34